Table 3.
Baseline characteristics of RA patients with high anti-MAA levels.
| IgG MAA low (n=227) | IgG MAA high# (n=176) | |||
|---|---|---|---|---|
| Frequency % Mean±SD (Median) | Frequency % Mean±SD (Median) | OR [CI] | p-values* | |
| Age | 50.7 ± 12.4 (53) | 50.1 ± 12.8 (53) | NS (p=0.64) | |
| Female | 72% (163/227) | 67% (118/176) | 1.3 [0.82-1.9] | NS (p=0.33) |
| HLA Shared epitope | 76% (172/225) | 78% (134/172) | 1.1 [0.66-1.7] | NS (p=0.81) |
| HLA DRB1*01 | 26% (59/224) | 21% (36/173) | 0.73 [0.46-1.2] | NS (p=0.23) |
| HLA DRB1*04 | 58% (129/224) | 61% (106/173) | 1.2 [0.78-1.75] | NS (p=0.47) |
| HLA DRB1*03 | 20% (45/224) | 19% (33/173) | 0.94 [0.57-1.5] | NS (p=0.90) |
| Smoking (present or previous) | 70% (159/226) | 73% (128/175) | 1.1 [0.74-1.8] | NS (p=0.58) |
| DAS28 | 4.8 ± 1.4 (5.1) | 5.3 ± 1.4 (5.5) | p<0.001 | |
| CRP | 24.5 ± 37.4 (12) | 33.4 ± 36.7 (18) | p=0.0008 | |
| IgG CCP2 levels (AU/ml) | 627 ± 913 (137) | 795 ± 989 (368) | p=0.006 | |
| IgG CCP2 pos | 63% (143/227) | 77% (135/176) | 1.9 [1.2-3.0] | p=0.003 |
| IgA CCP2 levels (AU/ml) | 5.8 ± 9.9 (1.6) | 6.7 ± 10.0 (2.2) | p=0.005 | |
| IgA CCP2 pos | 43% (96/223) | 53% (92/172) | 1.5 [1.1-2.3] | p=0.04 |
| Cit IgG fine-specificities | ||||
| Peptides with cit-gly motifs: | ||||
| Cit-Fil307-324 pos | 41% (90/221) | 47% (82/173) | 1.3 [0.87-1.96] | NS (p=0.22) |
| CEP-1 pos | 42% (92/221) | 54% (93/173) | 1.6 [1.1-2.4] | p=0.02 |
| Cit-Fibβ36-52 pos | 47% (104/221) | 58% (101/173) | 1.6 [1.1-2.4] | p=0.03 |
| Cit-Fibα563-583 pos | 42% (93/221) | 52% (90/173) | 1.5 [1-2.2] | NS (p=0.053) |
| Cit-Fibα580-600 pos | 25% (55/221) | 28% (49/173) | 1.1 [0.76-1.9] | NS (p=0.49) |
| Cit-Fibα621-635 pos | 30% (66/221) | 39% (67/172) | 1.5 [0.98-2.3] | NS (p=0.07) |
| Peptides with other motifs: | ||||
| Cit-Vim60-75 pos | 45% (99/221) | 51% (89/173) | 1.3 [0.87-1.95] | NS (p=0.22) |
| Cit-Vim2-17 pos | 35% (77/221) | 38% (65/173) | 1.1 [0.74-1.7] | NS (p=0.60) |
| Cit-Fibα36-50 pos | 12% (27/221) | 21% (36/172) | 1.9 [1.1-3.3] | p=0.03 |
| Cit-Fibβ60-74 pos | 58% (127/221) | 69% (118/172) | 1.6 [1.1-2.4] | p=0.03 |
| Number of ACPA fine-specificities (of 10) |
3.7 ± 3.3 [3] | 4.6 ± 3.2 [5] | p=0.01 | |
| AMPA IgG specificities | ||||
| ΔAc-His2B6-22 pos | 15% (35/227) | 19% (33/176) | 1.2 [0.70-2.1] | NS (0.59) |
| Carb-CEP1 pos | 22% (50/221) | 35% (60/173) | 1.8 [1.1-2.8] | p=0.009 |
| mod-Vim IgG Orn(Ac) pos | 53% (120/226) | 60% (105/175) | 1.3 [0.89-2.0] | NS (p=0.19) |
| mod-Vim IgG Carb pos | 46% (105/226) | 52% (91/175) | 1.2 [0.84-1.9] | NS (p=0.31) |
| mod-Vim IgG Lys(Ac) pos | 32% (72/226) | 34% (60/175) | 1.1 [0.73-1.7] | NS (p=0.67) |
| Carb-Fib pos | 41% (92/226) | 49% (86/175) | 1.4 [0.95-2.0] | NS (p=0.1) |
| Carb-FCS pos | 32% (72/226) | 47% (83/175) | 1.9 [1.3-2.9] | p=0.002 |
| RF | ||||
| IgG pos | 58% (131/227) | 63% (111/176) | 1.3 [0.84-1.9] | NS (0.31) |
| IgA pos | 40% (90/227) | 42% (74/176) | 1.1 [0.74-1.65] | NS (0.68) |
| IgM pos | 70% (158/227) | 73% (128/176) | 1.2 [0.75-1.8] | NS (0.51) |
#Cutoff 56.44 (85th percentile of 316 controls). *p-value from Fisher's exact test or Mann-Whitney analysis.
OR, Odds ratio; CI, 95% confidence interval; NS, Not statistically significant. Significant p-values are highlighted in bold font.